Skip to content
You are now leaving https://www.ionispharma.com to visit

New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)

NEURO-TTR phase 3 open-label extension study showed TEGSEDI ® ( inotersen) treatment continued to slow progression over two-year period in patients with Hereditary ATTR amyloidosis with polyneuropathy Ionis Logo Greater efficacy and clinical benefit observed with early initiation of TEGSEDI and no